WO2001051500A1 - Oligodeoxynucleotide and its use to induce an immune response - Google Patents
Oligodeoxynucleotide and its use to induce an immune response Download PDFInfo
- Publication number
- WO2001051500A1 WO2001051500A1 PCT/US2001/001122 US0101122W WO0151500A1 WO 2001051500 A1 WO2001051500 A1 WO 2001051500A1 US 0101122 W US0101122 W US 0101122W WO 0151500 A1 WO0151500 A1 WO 0151500A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- odn
- immune response
- host
- odns
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention pertains generally to induction of an immune response using different CpG sequences.
- DNA is a complex macromolecule whose immunological activities are influenced by its base composition and base modification, as well as helical orientation. Certain unusual DNA structures (e.g., Z-DNA) can induce significant antibody responses when administered to normal mice. In addition, bacterial DNA, as well as certain synthetic unmethylated CpG sequences can induce proliferation and immunoglobulin (Ig) production by murine B cells. Unmethylated CpG dinucleotides are more frequent in the genomes of bacteria and viruses than vertebrates, and recent studies suggest that immune recognition of these motifs may contribute to the host ' s innate immune response. D.M. Klinman et al..
- CpG DNA induces proliferation in almost all (>95%) of B cells and increases Ig secretion.
- This B cell activation by CpG DNA is T-cell independent and antigen non-specific.
- CpG DNA also directly activates monocytes, macrophages, and dendritic cells to secrete a variety of cytokines. These cytokines stimulate natural killer (NK) cells to secrete ⁇ -interferon (IFN- ⁇ ) and have increased lytic activity. Examples of which can be found in International Patent Applications WO 95/26204. WO 96/02555. WO 98/1 121 1. WO 98/18810, WO 98/37919, WO 98/40100. WO 98/52581 : U.S. Patent Application Nos. 08/738,652; and U.S. Patent No. 5.663,153.
- the present invention provides a substantially pure or isolated oligodeoxynucleotide (ODN) of at least about 10 nucleotides comprising multiple CpG sequences, wherein at least one of the CpG sequences is different from another of the multiple CpG sequences.
- ODN oligodeoxynucleotide
- the present invention also provides an ODN delivery complex and a pharmacological composition comprising an ODN or ODNs. as well as a method of inducing an immune response by administering an ODN or ODNs to a host.
- the present invention is based on the discovery that different CpG sequences, which are formulated either as multiple individual oligodeoxynucleotides (ODNs) each comprising a single CpG motif, or a complex ODN comprising multiple CpG sequences, induces an enhanced immune response in a broad population.
- ODNs oligodeoxynucleotides
- the present invention provides novel ODNs. These ODNs have at least about 10 nucleotides and comprise multiple (i.e.. 2 or more) CpG sequences, wherein at least one of the multiple CpG sequences is different from another of the multiple CpG sequences.
- a "CpG sequence " or "CpG motif " refers to a nucleic acid sequence having a cytosine followed by a guanine linked by a phosphate bond in which the cytosine is unmethylated.
- the ODNs of the present invention comprise multiple different
- two, three, or more of the multiple different sequences can be represented by either the formula 5' N*N 2 N 3 T- CpG-WN 4 N 5 N 6 3', wherein W is A or T, and N b N 2 .
- N 3 , N 4 , N 5 , and N 6 are any nucleotides, or the formula 5' RY-CpG-RY 3'. wherein R is A or G and Y is C or T.
- R is A or G
- Y is C or T.
- at least one of the different CpG sequences can be selected from the group consisting of SEQ ID NO: 1 through SEQ ID NO: 1 12.
- two. three, or more of the different CpG sequences can be selected from the group consisting of SEQ ID NO: l through SEQ ID NO:l 12.
- the ODN of the present invention is substantially pure or isolated.
- substantially pure refers to an ODN that is substantially free of other materials, particularly other nucleic acids, proteins, lipids, carbohydrates, and other materials with which it may be naturally associated, while “isolated” refers to an ODN that is removed from its natural environment or state.
- the ODN of the present invention can consist of any suitable number of nucleotides.
- the ODN can consist of about 100 nucleotides or less (e.g., about 10-75 nucleotides) or about 50 nucleotides or less (e.g., about 10-40 nucleotides).
- the ODNs inducing a humoral immune response e.g., those containing at least one sequence represented by the formula 5' N ⁇ N 2 N 3 T-CpG-
- WN 4 N 5 N 6 3' contain a phosphate backbone modification, and more preferably, the phosphate backbone modification is a phosphorothioate backbone modification (i.e., one of the non-bridging oxygens is replaced with sulfur, as set forth in International Patent Application WO 95/26204).
- the ODNs inducing a cell-mediated immune response and containing a phosphodiester backbone e.g., those containing at least one sequence represented by the formula 5' RY-CpG-RY 3', the ODN preferably has been modified to prevent degradation.
- any suitable modification can be used in the present invention to render the ODN resistant to in vivo degradation resulting from, e.g., exo or endonuclease digestion.
- the modification includes a phosphorothioate modification.
- the phosphorothioate modifications can occur at either termini, e.g.. the last two or three 5' and/or 3' nucleotides can be liked with phosphorothioate bonds.
- the ODN also can be modified to contain a secondary structure (e.g., stem loop structure) such that it is resistant to degradation.
- Another modification that renders the ODN less susceptible to degradation is the inclusion of nontraditional bases such as inosine and quesine, as well as acetyl-.
- modified nucleotides include nonionic DNA analogs, such as alkyl or aryl phosphonates (i.e.. the charged phosphonate oxygen is replaced with an alkyl or aryl group, as set forth in U.S. Patent No. 4,469,863), phosphodiesters and alkylphosphotriesters (i.e., the charged oxygen moiety is alkylated, as set forth in U.S. Patent No. 5,023,243 and European Patent No. 0 092 574).
- ODNs containing a diol, such as tetraethyleneglycol or hexaethyleneglycol, at either or both termini, have also been shown to be more resistant to degradation. Oligodeoxynucleotide Delivery Complex
- the present inventive ODN delivery complex can comprise multiple (i.e., more than one) substantially pure or isolated ODNs of at least about 10 nucleotides comprising a CpG sequence and a targeting means, wherein at least one of the CpG sequences is different from another of the multiple CpG sequences. Therefore, the present inventive ODN delivery complex can comprise multiple ODNs comprising a single CpG sequence with at least one of these multiple ODNs comprising a CpG sequence that is different from the CpG sequences comprised by another ODN within the complex. Additionally, the present inventive ODN delivery complex can comprise a single ODN or multiple ODNs comprising multiple different CpG sequences and a targeting means. Therefore, the present inventive ODN delivery complex can comprise either a single ODN, or multiple (i.e., more than one) ODNs.
- Any suitable targeting means i.e., a molecule that results in higher affinity binding to a target cell
- Any suitable targeting means i.e., a molecule that results in higher affinity binding to a target cell
- the ODN delivery complex can be associated with (e.g., ionically or covalently bound to, or encapsulated within) the targeting means by a variety of coupling or cross-linking agents, e.g., protein A, carbodiamide, and N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP).
- Examples of ODN delivery complexes include ODNs associated with a sterol (e.g., cholesterol), a lipid (e.g., a cationic lipid, virosome or liposome), and a target cell specific binding agent (e.g., a ligand recognized by target cell specific receptor).
- Preferred complexes must be sufficiently stable in vivo to prevent significant uncoupling prior to internalization by the target cell; however, these complexes can be cleavable under appropriate circumstances such that the ODN can be released in a functional form.
- the present inventive composition can comprise multiple substantially pure or isolated ODNs of at least about 10 nucleotides comprising a CpG sequence and a pharmacologically acceptable carrier, wherein at least one of the CpG sequences is different from another of the multiple CpG sequences. Therefore, the present inventive pharmacological composition can comprise multiple ODNs comprising a single CpG sequence and at least one of these multiple ODNs comprises a CpG sequence that is different from the CpG sequences comprised by another ODN within the composition. Additionally, the present inventive pharmaceutical composition can comprise a single ODN or multiple ODNs comprising multiple different CpG sequences and a pharmacologically acceptable carrier. Therefore, the present inventive pharmaceutical composition can comprise either a single ODN.
- ODNs multiple (i.e., more than one) ODNs.
- Pharmacologically acceptable carriers e.g.. physiologically or pharmaceutically acceptable carriers
- the present inventive pharmacological composition facilitates the use of the one or more present inventive ODNs, both in vivo and ex vivo.
- Such a composition can be suitable for delivery of the active ingredient to any suitable host, such as a patient for medical application, and can be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
- Pharmacological compositions for use in accordance with the present invention can be formulated in a conventional manner using one or more pharmacologically (e.g.. physiologically or pharmaceutically) acceptable carriers comprising excipients, as well as optional auxiliaries that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
- the active ingredient can be formulated in aqueous solutions, preferably in physiologically compatible buffers.
- penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
- the active ingredient can be combined with carriers suitable for inclusion into tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like.
- the active ingredient is conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant.
- the active ingredient can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
- Such compositions can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- Other pharmacological excipients are known in the art.
- the present inventive method of inducing an immune response can comprise administering to a host multiple substantially pure or isolated ODNs of at least about 10 nucleotides comprising a CpG sequence in order to induce an immune response in the host, wherein at least one of the CpG sequences is different from another of the multiple CpG sequences. Therefore, the present inventive method can comprise administering to a host multiple ODNs comprising a single CpG sequence and at least one of these multiple ODNs comprises a CpG sequence that is different from the CpG sequences comprised by another ODN administered to a host.
- the present inventive method of inducing an immune response can comprise administering to a host a single ODN or multiple ODNs comprising multiple different CpG sequences in order to induce an immune response in the host. Therefore, the present inventive method of inducing an immune response can comprise administering either a single ODN or multiple (i.e., more than one) ODNs to a host in order to induce an immune response in the host.
- the ODN or ODNs can be administered in vivo or ex vivo.
- the ODN or ODNs are administered in vivo to a mammal, particularly a human.
- the ODN or ODNs can be contained within or conjugated with a larger nucleic acid molecule, protein, hydrocarbon or lipid. Once this molecule is administered, the CpG sequences must be exposed on the surface to induce an immune response.
- suitable nucleic acid molecules include fusion or chimeric nucleic acids, proteins, hydrocarbons and lipids.
- the ODN or ODNs can also be co-administered with another nucleic acid, protein, hydrocarbon, or lipid.
- Co-administration can be such that the ODN or ODNs are administered before, at substantially the same time as, or after the other nucleic acid, protein, hydrocarbon, or lipid.
- the ODN or ODNs are administered at substantially the same time as the other nucleic acid, protein, hydrocarbon, or lipid.
- ODN antigen presenting cells
- cytokines which activate natural killer (NK) cells.
- NK natural killer
- T cells which are able to detect the presence of invading pathogens through a recognition system referred to as the T cell antigen receptor.
- T cells direct the release of multiple T cell cytokines, including IL-2, IL-3, IFN- ⁇ , TNF- ⁇ . GM- CSF and high levels of TNF- ⁇ , and chemokines MlP-l ⁇ , MlP-l ⁇ . and RANTES.
- IL-2 is a T cell growth factor that promotes the production of additional T cells sensitive to the particular antigen. This production constitutes a clone of the T cells.
- the sensitized T cells attach to cells containing the antigen.
- T cells carry out a variety of regulatory and defense functions and play a central role in immunologic responses. When stimulated to produce a cell-mediated immune response, some T cells respond by acting as killer cells, killing the host's own cells when these cells are infected or cancerous and therefore recognized as foreign. Some T cells respond by stimulating B cells, while other T cells respond by suppressing immune response. If a cell-mediated immune response is induced, preferably, non-B cells are activated, more preferably, cytokines are produced, and most preferably, IFN- ⁇ is produced.
- the humoral or systemic immune response depends on the ability of the B cells to recognize specific antigens. The mechanism by which B cells recognize antigens is through specific receptors on the surface of the B cells.
- B cells When an antigen attaches to the receptor site of a B cell, the B cell is stimulated to divide. The daughter cells become plasma cells that manufacture antibodies complementary to the attached antigen. Each plasma cell produces thousands of antibody molecules per minute, which are released into the bloodstream. Many B cells appear to be regulated by the helper T cells and suppressor T cells and produce various cytokines, e.g., IL-3, IL-4, IL-5, IL-6. IL-9, IL-10, IL-13. GM-CSF and low levels of TNF- ⁇ . Helper T cells stimulate B cells to produce antibodies against antigens, while suppressor T cells inhibit antibody production. Some B cells, however, are T cell independent and require no stimulation by the T cells. If a humoral immune response is induced. preferably, B cells are activated, more preferably, IL-6 is produced, and most preferably, antibodies are produced.
- induction of one type of immune response may allow for immune regulation because up regulation of one type of immune response may down regulate the other type of immune response.
- This immune regulation allows for customizing or tailoring of the type of immune response when administering an ODN.
- the present inventive method of inducing an immune response can be used to treat, prevent, or ameliorate any suitable allergic reaction.
- the present inventive method can be used in combination with any suitable anti-allergenic agent.
- An allergy in the context of the present invention, refers to an acquired hypersensitivity to a substance (i.e.. an allergen). Allergic conditions include eczema, allergic rhinitis or coryza. hay fever, bronchial asthma, uticaria (hives), food allergies, and other atopic conditions.
- allergens is extensive and inc'udes pollens, insect venoms, animal dander, dust, fungal spores, and drugs (e.g.. penicillin).
- Suitable anti-allergenic agents include those substances given in treatment of the various allergic conditions described above, examples of which can be found in the Physicians' Desk Reference (1998).
- the present inventive method of inducing an immune response can be used to treat any suitable cancer.
- the present inventive method can be used in combination with any suitable anti-cancer agent.
- suitable cancers include cancers of the brain, lung (e.g., small cell and non-small cell), ovary, breast, prostate, and colon, as well as carcinomas and sarcomas.
- the present inventive method is used to treat a solid tumor cancer.
- Suitable anti-cancer agents include those substances given in treatment of the various conditions described above, examples of which can be found in the Physicians' Desk Reference (1998).
- the present inventive method of inducing an immune response can be used to improve the efficacy of any suitable vaccine.
- Suitable vaccines include those directed against Hepatitis A, B. and C, examples of which can be found in the Physicians " Desk Reference (1998), and DNA vaccines directed against HIV and malaria. See generally D. Klinman et al., CpG Motifs as Immune Adjuvants. 17
- CpG DNA is a Potent Enhancer of Systemic & Mucosal Immune Response against Hepatitis B Surface Antigen with Intra-Nasal Administration to Mice, 161 J. Immun. 4463 (1998).
- the present inventive method of inducing an immune response can be used to treat, prevent, or ameliorate any suitable disease associated with the immune system.
- Preferred diseases associated with the immune system are autoimmune disorders and immune system deficiencies, e.g., lupus eryfhematosus. and autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.
- Immune system deficiencies include those diseases or disorders in which the immune system is not functioning at normal capacity, or in which it would be useful to boost the immune system response.
- the present inventive method of inducing an immune response can be used with any suitable antisense therapy.
- the present inventive method can be used in combination any suitable antisense agent.
- Suitable antisense agents are those that bind either with DNA or RNA and block their function by inhibiting expression of the sequence to which the antisense agents are bound. See generally H. Lonnberg et al.. Towards Genomic Drug Therapy with Antisense Oligonucleotides. 28 Ann. Med. 51 1 (1996); A. Alama et al., Antisense Oligonucleotides as Therapeutic Agents. 36 Pharmacol. Res. 171 (1997); K.J. Scanlon et al., Oligonucleotide-Mediated Modulation of Mammalian Gene Expression, 9 FASEB J. 1288 (1995); R. Oberbauer, Not Non-Sense but Antisense — Applications of Antisense
- the present inventive method of inducing an immune response can be used to treat, prevent, or ameliorate any suitable infection.
- the present inventive method can be used in combination with any suitable anti-infectious agent.
- infections include francisella, schistosomiasis. tuberculosis, AIDS, malaria, and leishmania.
- suitable infectious viruses, bacteria, fungi, and other organisms e.g., protists
- Suitable anti-infectious agents include those substances given in treatment of the various conditions described elsewhere, examples of which can be found in the Physicians' Desk Reference (1998).
- the present inventive method of inducing an immune response can be used to treat, prevent, or ameliorate the symptoms resulting from exposure to a bio-warfare agent.
- Suitable bio-warfare agents include those naturally occurring biological agents that have been specifically modified in the laboratory. Often, modification of these agents has altered them such that there is no known treatment. Examples include Ebola, Anthrax, and Listeria.
- use of the present inventive ODNs may not cure the patient, but rather can extend the patient's life sufficiently such that some other treatment can then be applied.
- the present invention is further described in the following examples. These examples are intended only to illustrate the invention and are not intended to limit the scope of the invention in any way.
- the following example demonstrates the varied immune response induced in vitro in different donors after administration of an ODN comprising a single CpG sequence.
- Induction of an immune response was measured by production of the cytokines IL-6 and IFN- ⁇ , and cell proliferation in human peripheral blood mononuclear cells (PBMC) isolated from individual donors.
- PBMC peripheral blood mononuclear cells
- PBMC peripheral blood mononuclear cells
- ODNs were synthesized on a DNA synthesizer (Applied Biosystems Inc., Foster City, CA), as described elsewhere (Beacage and Caruthers, Deoxynucleoside Phosphoramidites - A New Class of Key Intermediates for Deoxypolynucleotide Synthesis. 22 Tetrahedron Letters 1859 (1981)). In some ODNs.
- IL-6 levels are set forth in Table 1 : Induction of an Immune Response (IL-6), IFN- ⁇ levels are set forth in Table 5: Induction of an Immune Response (IFN- ⁇ ), and cell proliferation is set forth in Table 6: Induction of an Immune Response (Cell Proliferation).
- the foregoing data demonstrates induction of an immune response to an ODN comprising various sequences in human PBMC isolated from individual donors. Specifically, these data demonstrate that a single sequence induces a varied immune response in different donors, as show, e.g., in Table 4, an ODN comprising SEQ ID NO:98 induced IL-6 levels ranging from 2 to 80, in Table 5, an ODN comprising SEQ ID NO:42 induced IFN- ⁇ levels ranging from 4 to 419, and in Table 6, an ODN comprising SEQ ID NO: 15 induced cell proliferation ranging from 9 to 47.
- the following example demonstrates the varied immune responses induced in vitro in different donors after administration of an ODN comprising a single CpG sequence. Induction of an immune response was measured by production of the cytokines IL-6 and IFN- ⁇ in human PBMC isolated from individual donors as compared to unstimulated PBMC from the same donor.
- Human PBMC were isolated, as described in Example 1.
- ODNs were synthesized on a DNA synthesizer (Applied Biosystems Inc., Foster City, CA), as described in Example 1.
- the normal DNA backbone phosphodiesterase linkages were replaced with phosphorothioate linkages, as described in Example 1.
- those that did not have an entire phosphorothioate backbone contained phosphorothioate linkages at the 5' and 3' ends.
- Cells were incubated for approximately 72 hrs with the various ODNs.
- IL-6 and IFN- ⁇ levels were determined by ELISA using anti-IL-6 and anti-IFN- ⁇ antibodies, as described in Example 1.
- IL-6 levels in Table 4 Percent Induction of an Immune Response (IL-6) and for IFN- ⁇ levels in Table 5: Induction of an Immune Response (IFN- ⁇ ).
- IL-6 levels in Table 6 Percent Induction of an Immune Response (IL-6) and for IFN- ⁇ levels in Table 5: Induction of an Immune Response (IFN- ⁇ ).
- greater than a 3-fold increase for IL-6 and greater than a 5-fold increase for IFN- ⁇ is represented by "+ " 'and any levels lower than this are represented by "— ".
- These profiles are set forth for IL-6 in Table 6: Heterogeneity in Induction of an Immune Response (IL-6) and for IFN- ⁇ in Table 7: Heterogeneity in Induction of an Immune Response (IFN- ⁇ ).
- the foregoing data demonstrates induction of an immune response to an ODN comprising various sequences in human PBMC isolated from individual donors. Specifically, these data demonstrate that a single sequence induces a varied immune response in different donors, as show, e.g., in Table 4, the percent of donors induced varied from 7% to 69%. as measured by IL-6 production, and in Table 5. the percent of donors induced varied from 11% to 93%, as measured by IFN- ⁇ production. Further, as demonstrated in Tables 6 and 7, there was substantial heterogeneity in induction of an immune response in different donors.
- the following example demonstrates in vitro induction of an immune response after administration of multiple ODNs comprising a CpG sequence.
- Induction of an immune response was measured by production of the cytokines IL-6 and IFN- ⁇ , and cell proliferation in human PBMC isolated from individual donors.
- Human PBMC were isolated, as described in Example 1.
- ODNs were synthesized on a DNA synthesizer (Applied Biosystems Inc., Foster City, CA). as described in Example 1.
- the normal DNA backbone phosphodiesterase linkages were replaced with phosphorothioate linkages, as described in Example 1. To reduce degradation of the ODNs.
- the foregoing data demonstrates the induction of an immune response after administration of multiple ODNs comprising various CpG sequences in human PBMC isolated from individual donors.
- these data demonstrate that multiple ODNs synergistically induce an immune response, as demonstrated by, e.g., an increase of 26.6% as measured by cell proliferation, 29.6% as measured by IL-6 levels and 71.7% as measured by IFN- ⁇ levels after administration to Donor 1 of a combination of an ODN comprising SEQ ID NO:l and an ODN comprising SEQ ID NO:43 compared to the combined immune response of each ODN administered separately.
- the following example demonstrates in vitro induction of an immune response after administration of multiple ODNs comprising a CpG sequence. Induction of an immune response was measured by production of the cytokines IL-6 and IFN- ⁇ in human PBMC isolated from individual donors as compared to unstimulated PBMC from the same donor.
- Human PBMC were isolated, as described in Example 1.
- ODNs were synthesized on a DNA synthesizer (Applied Biosystems Inc., Foster City, CA). as described in Example 1.
- the normal DNA backbone phosphodiesterase linkages were replaced with phosphorothioate linkages, as described in Example 1.
- those that did not have an entire phosphorothioate backbone contained phosphorothioate linkages at the 5' and 3' ends.
- Cells were incubated for approximately 72 hrs with the various ODNs.
- IL-6 and IFN- ⁇ levels were determined by ELISA using anti-IL-6 and anti-IFN- ⁇ antibodies, as described in Example 1.
- IL-6 levels Percent Induction of an Immune Response (IL-6) and for IFN- ⁇ levels in Table 10: Induction of an Immune Response (IFN- ⁇ ).
- the foregoing data demonstrates the induction of an immune response after administration of multiple ODNs comprising various CpG sequences in human PBMC isolated from individual donors.
- these data demonstrate that multiple ODNs synergistically induce an immune response, as demonstrated by, e.g.. Table 9. in which the percent induction was increased in two of the multiple ODNs to 100%. as measured by IL-6 production. This is also show in Table 10, in which the percent induction was increased to 100% for three of the multiple ODNs, as measured by IFN- ⁇ production.
- the following example demonstrates in vitro induction of an immune response after administration of a single ODN comprising multiple different CpG sequences. Induction of an immune response was measured by production of the cytokines IL-6 and IFN- ⁇ , and cell proliferation in human PBMC isolated from individual donors.
- the foregoing data demonstrates the induction of an immune response after administration of a single ODN comprising multiple different CpG sequences in human PBMC isolated from individual donors.
- these data demonstrate that a single ODN comprising multiple different CpG sequences synergistically induces an immune response, such as is demonstrated by, e.g., an increase in IL-6 levels of 65.2% in Donor 1 and 53.3% in Donor 2 after administration of a single ODN comprising SEQ ID NO:l and SEQ ID NO:43 compared to the combined immune response of a single ODN comprising either SEQ ID NO: l or SEQ ID NO:43 when administered separately.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001227889A AU2001227889A1 (en) | 2000-01-14 | 2001-01-12 | Oligodeoxynucleotide and its use to induce an immune response |
DE60131430T DE60131430T2 (en) | 2000-01-14 | 2001-01-12 | OLIGODE OXYNUCLEOTIDES AND THEIR USE FOR INDUCING AN IMMUNE REACTION |
EP01902045A EP1322655B1 (en) | 2000-01-14 | 2001-01-12 | Oligodeoxynucleotide and its use to induce an immune response |
US10/194,035 US7521063B2 (en) | 2000-01-14 | 2002-07-12 | Multiple CPG oligodeoxynucleotides and their use to induce an immune response |
US11/801,984 US7919477B2 (en) | 2000-01-14 | 2007-05-10 | Multiple CpG oligodeoxynucleotides and their use to induce an immune response |
US13/026,032 US8232259B2 (en) | 2000-01-14 | 2011-02-11 | Multiple CpG oligodeoxynucleotide and their use to induce an immune response |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17611500P | 2000-01-14 | 2000-01-14 | |
US60/176,115 | 2000-01-14 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/194,035 Continuation-In-Part US7521063B2 (en) | 2000-01-14 | 2002-07-12 | Multiple CPG oligodeoxynucleotides and their use to induce an immune response |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001051500A1 true WO2001051500A1 (en) | 2001-07-19 |
Family
ID=22643035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/001122 WO2001051500A1 (en) | 2000-01-14 | 2001-01-12 | Oligodeoxynucleotide and its use to induce an immune response |
Country Status (6)
Country | Link |
---|---|
US (3) | US7521063B2 (en) |
EP (1) | EP1322655B1 (en) |
AT (1) | ATE378348T1 (en) |
AU (1) | AU2001227889A1 (en) |
DE (1) | DE60131430T2 (en) |
WO (1) | WO2001051500A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003014316A2 (en) | 2001-08-07 | 2003-02-20 | Dynavax Technologies Corporation | Immunomodulatory compositions, formulations, and methods for use thereof |
WO2003020884A2 (en) * | 2001-08-14 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for rapid generation of mature dendritic cells |
WO2004078772A1 (en) * | 2003-03-03 | 2004-09-16 | Doo-Sik Kim | Oligonucleotides for stimulating immune response |
EP1572122A2 (en) * | 2002-11-01 | 2005-09-14 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides |
WO2005001055A3 (en) * | 2003-06-11 | 2005-10-13 | Hybridon Inc | Stabilized immunomodulatory oligonucleotides |
US7129222B2 (en) | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US7250403B2 (en) | 2000-03-10 | 2007-07-31 | Dynavax Technologies Corporation | Biodegradable immunomodulatory formulations and methods for use thereof |
EP1992635A1 (en) | 2002-12-23 | 2008-11-19 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US7521063B2 (en) * | 2000-01-14 | 2009-04-21 | The United States Of America As Represented By The Department Of Health And Human Services | Multiple CPG oligodeoxynucleotides and their use to induce an immune response |
US8030285B2 (en) | 1999-04-12 | 2011-10-04 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
WO2012160153A1 (en) | 2011-05-24 | 2012-11-29 | Assistance Publique - Hopitaux De Paris | Agents for treating tumours |
US8372413B2 (en) | 2000-12-27 | 2013-02-12 | Dynavax Technologies Corporation | Immunomodulatory polynucleotides and methods of using the same |
US8871732B2 (en) | 2002-12-23 | 2014-10-28 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US9028845B2 (en) | 2001-06-21 | 2015-05-12 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same-IV |
WO2016103703A1 (en) * | 2014-12-25 | 2016-06-30 | 国立研究開発法人医薬基盤・健康・栄養研究所 | Non-aggregating immunostimulatory oligonucleotides |
WO2016183371A1 (en) | 2015-05-13 | 2016-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for the treatment or prevention of ischemic tissue damage |
WO2016183370A1 (en) | 2015-05-13 | 2016-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Synthetic immunosuppressive oligodeoxynucleotides reduce ischemic tissue damage |
US9809824B2 (en) | 2004-12-13 | 2017-11-07 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods |
WO2017192874A1 (en) | 2016-05-04 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Albumin-binding immunomodulatory compositions and methods of use thereof |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
JP2005503320A (en) * | 2000-08-25 | 2005-02-03 | イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド | Methods for treating or preventing autoimmune diseases with CpG-containing polynucleotides |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
AU2002366710A1 (en) * | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
US7807803B2 (en) * | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040053880A1 (en) * | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
AR040996A1 (en) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | IMMUNE STIMULATING NUCLEIC ACIDS |
US8263091B2 (en) * | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
AU2003300919A1 (en) * | 2002-12-11 | 2004-06-30 | Coley Pharmaceutical Gmbh | 5' cpg nucleic acids and methods of use |
US7910523B2 (en) | 2003-05-23 | 2011-03-22 | Board Of Regents, The University Of Texas System | Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors |
CA2536139A1 (en) * | 2003-09-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
CA2540949A1 (en) * | 2003-10-30 | 2005-05-12 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
CN101160401A (en) * | 2005-02-24 | 2008-04-09 | 科勒制药集团公司 | Immunostimulatory oligonucleotides |
NZ561144A (en) * | 2005-03-04 | 2009-09-25 | Dynavax Tech Corp | Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients |
JP5659332B2 (en) | 2008-06-27 | 2015-01-28 | ゾエティス・エルエルシー | Novel adjuvant composition |
PT2376107E (en) | 2008-12-09 | 2014-07-25 | Coley Pharm Group Inc | Immunostimulatory oligonucleotides |
US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
AU2010229835B2 (en) | 2009-03-25 | 2015-01-15 | The Board Of Regents Of The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
ES2352780B2 (en) | 2009-06-04 | 2011-09-15 | Laboratorios Ovejero S.A. | LIPOPOLISACÁRIDO DE OCHROBACTRUM INTERMEDIUM AGAINST SEPSIS. |
US10076535B2 (en) * | 2012-04-27 | 2018-09-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of CPG oligonucleotides co-formulated with an antibiotic to accelerate wound healing |
KR102257743B1 (en) | 2013-09-19 | 2021-05-28 | 조에티스 서비시즈 엘엘씨 | Oil-based adjuvants |
US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
PL3244920T3 (en) | 2015-01-16 | 2023-09-25 | Zoetis Services Llc | Foot-and-mouth disease vaccine |
US11168326B2 (en) | 2017-07-11 | 2021-11-09 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
CA3176812A1 (en) | 2018-07-11 | 2020-01-16 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
WO2020047161A2 (en) | 2018-08-28 | 2020-03-05 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
WO2020176809A1 (en) | 2019-02-27 | 2020-09-03 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
JP2023501539A (en) | 2019-11-12 | 2023-01-18 | アクティム・セラピューティクス・インコーポレイテッド | An immunostimulatory bacterial delivery platform and its use for delivery of therapeutic products |
CN111057709A (en) * | 2019-11-13 | 2020-04-24 | 吉林农业大学 | Pig specificity CpG oligodeoxynucleotide and application thereof |
CA3191433A1 (en) | 2020-08-12 | 2022-02-17 | Actym Therapeutics, Inc. | Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998018810A1 (en) * | 1996-10-30 | 1998-05-07 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
WO1998040100A1 (en) * | 1997-03-10 | 1998-09-17 | Ottawa Civic Loeb Research Institute | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT |
WO1998049288A1 (en) * | 1997-04-30 | 1998-11-05 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and in vivo protection from infection |
WO1998052581A1 (en) * | 1997-05-20 | 1998-11-26 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
WO1998055495A2 (en) * | 1997-06-06 | 1998-12-10 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
WO1999051259A2 (en) * | 1998-04-03 | 1999-10-14 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
WO1999056755A1 (en) * | 1998-05-06 | 1999-11-11 | University Of Iowa Research Foundation | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
WO1999058118A2 (en) * | 1998-05-14 | 1999-11-18 | Cpg Immunopharmaceuticals Gmbh | METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES |
Family Cites Families (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2001A (en) * | 1841-03-12 | Sawmill | ||
US2215233A (en) * | 1937-11-13 | 1940-09-17 | Simon L Ruskin | Iron compound of nucleotides and their organic hydrolytic decomposition products and method of making same |
US3906092A (en) * | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
US3911117A (en) * | 1971-12-20 | 1975-10-07 | Fredrik Ender | Raw fish and iron chelated with glutamic or ribonucleic acid in a mink diet |
US3914450A (en) * | 1973-04-09 | 1975-10-21 | Anheuser Busch | Concentrated extract of yeast and processes of making same |
US4469863A (en) * | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
JP2547714B2 (en) | 1981-10-23 | 1996-10-23 | モルキユラ− バイオシステムズ インコ−ポレテツド | Oligonucleotide therapeutic agent and method for producing the same |
US5023243A (en) * | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
ES507187A0 (en) * | 1981-11-16 | 1983-01-01 | Union Ind Y Agro Ganader S A U | PROCEDURE FOR OBTAINING AN ADDITIONAL HUMANIZED MILK OF NUCLEOTIDES FOR CHILD FEEDING. |
JPS60126220A (en) * | 1983-12-09 | 1985-07-05 | Otsuka Pharmaceut Factory Inc | Nucleic acid component composition |
US4741914A (en) * | 1984-11-13 | 1988-05-03 | Ajinomoto Co., Inc. | Flavor enhancing seasoning containing deodorized garlic extract and process |
US4956296A (en) * | 1987-06-19 | 1990-09-11 | Genex Corporation | Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G |
JPS62275667A (en) * | 1986-05-22 | 1987-11-30 | Ajinomoto Co Inc | Production of seasoning with good body or food with enhanced good body |
DE3867308D1 (en) * | 1987-05-20 | 1992-02-13 | Chugai Pharmaceutical Co Ltd | SALT REPLACEMENT AND FOOD CONTAINING THIS. |
ES2007350A6 (en) * | 1987-05-29 | 1989-06-16 | Ganadera Union Ind Agro | Food products enriched with nucleosides and/or nucleotides and preparation thereof. |
JP2656571B2 (en) * | 1987-11-17 | 1997-09-24 | 三井東圧化学株式会社 | Tetraphenylthiophene derivative and electrophotographic photoreceptor containing the same |
US5268365A (en) * | 1988-03-11 | 1993-12-07 | Rudolph Frederick B | Nucleotides, nucleosides, and nucleobases in immune function restoration enhancement or maintenance |
CA1336174C (en) * | 1988-07-22 | 1995-07-04 | Ronald Peter Potman | Method for the preparation of a yeast extract said yeast extract, its use as a food flavour and a food composition comprising the yeast extract |
US5231085A (en) * | 1988-10-31 | 1993-07-27 | Sandoz Ltd. | Compositions and methods for the enhancement of host defense mechanisms |
US5786189A (en) * | 1989-11-29 | 1998-07-28 | Smithkline Beecham Biologicals (S.A.) | Vaccine |
US5248670A (en) * | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
US5514577A (en) | 1990-02-26 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide therapies for modulating the effects of herpes viruses |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
US5234811A (en) * | 1991-09-27 | 1993-08-10 | The Scripps Research Institute | Assay for a new gaucher disease mutation |
US5683985A (en) | 1991-04-18 | 1997-11-04 | The Salk Institute For Biological Studies | Oligonucleotide decoys and methods relating thereto |
US6022853A (en) * | 1991-08-30 | 2000-02-08 | Creative Biomolecules, Inc. | Morphogen-enriched dietary composition |
WO1993017115A2 (en) | 1992-02-18 | 1993-09-02 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Dysentery vaccine stimulating an immune response against shigatoxin, plasmids and host strains for it |
ATE260971T1 (en) * | 1992-04-01 | 2004-03-15 | Univ Rockefeller | METHOD FOR THE IN VITRO CULTIVATION OF DENDRITIC PRECURSOR CELLS AND THEIR USE FOR IMMUNOGENIC PRODUCTION |
EP0572735B1 (en) | 1992-06-04 | 1998-11-25 | VYSIS, Inc. | Nucleic acid probes for the detection of Mycoplasma fermentans |
US5585479A (en) * | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
AU678415B2 (en) * | 1992-10-05 | 1997-05-29 | Hybridon, Inc. | Therapeutic anti-HIV oligonucleotide and pharmaceutical |
US5650156A (en) * | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
AU7319994A (en) * | 1993-06-30 | 1995-01-24 | Board Of Regents, The University Of Texas System | Nucleotide preparation and uses thereof in wound healing |
US5849719A (en) * | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
US5804566A (en) * | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
GB9326425D0 (en) | 1993-12-24 | 1994-02-23 | Secr Defence | Vaccine compositions |
US5492899A (en) * | 1994-01-10 | 1996-02-20 | Abbott Laboratories | Infant nutritional formula with ribo-nucleotides |
US5488039A (en) * | 1994-01-10 | 1996-01-30 | Abbott Laboratories | Method for the production of an enteral formula containing ribo-nucleotides |
US5602109A (en) * | 1994-01-10 | 1997-02-11 | Abbott Laboratories | Method to enhance the immune system of a human |
US5700590A (en) * | 1994-01-10 | 1997-12-23 | Abbott Laboratories | Nutritional formula with ribo-nucleotides |
EP0672354B1 (en) * | 1994-03-18 | 2000-07-12 | Ajinomoto Co., Inc. | Proteinaceous material for enhancing food taste quality |
WO1995026204A1 (en) * | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
ES2267100T5 (en) | 1994-07-15 | 2011-04-08 | The University Of Iowa Research Foundation | IMMUNOMODULATING OLIGONUCLEOTIDES. |
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5591721A (en) * | 1994-10-25 | 1997-01-07 | Hybridon, Inc. | Method of down-regulating gene expression |
US6428788B1 (en) * | 1995-03-15 | 2002-08-06 | Penn State University | Compositions and methods for specifically targeting tumors |
US5614191A (en) * | 1995-03-15 | 1997-03-25 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
JP3580900B2 (en) * | 1995-04-20 | 2004-10-27 | ホクレン農業協同組合連合会 | Food and feed containing, as an active ingredient, a composition mainly comprising a sugar containing an α-glucosidase inhibitor |
US5612060A (en) * | 1995-05-25 | 1997-03-18 | Alexander; J. Wesley | Enhancement of transplant graft survival through nutritional immunomodulation and immunosuppressive therapy |
US5976580A (en) * | 1995-06-07 | 1999-11-02 | Novus International, Inc. | Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals |
GB9525902D0 (en) * | 1995-12-16 | 1996-02-21 | Zeneca Ltd | Fungus |
JP4359654B2 (en) | 1996-01-30 | 2009-11-04 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | Gene expression vector for generating antigen-specific immune response and method of use thereof |
US5895652A (en) * | 1996-07-29 | 1999-04-20 | Longevity Institute International | Method of metabolic adjuvanation and cellular repair |
US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
US6610661B1 (en) * | 1996-10-11 | 2003-08-26 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
EP0855184A1 (en) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
AU738513B2 (en) | 1997-02-28 | 2001-09-20 | University Of Iowa Research Foundation, The | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6589940B1 (en) * | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US5922766A (en) * | 1997-07-02 | 1999-07-13 | Acosta; Phyllis J. B. | Palatable elemental medical food |
JP4663113B2 (en) | 1997-09-05 | 2011-03-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Use of immunostimulatory oligonucleotides to prevent or reduce antigen-stimulated granulocyte-mediated inflammation |
PL345241A1 (en) | 1998-05-06 | 2001-12-03 | Upjohn Co | Introduction of naked dna or rna encoding non-human vertebrate peptide hormones or cytokines into a non-human vertebrate |
DE69932717T2 (en) | 1998-05-22 | 2007-08-09 | Ottawa Health Research Institute, Ottawa | METHODS AND PRODUCTS FOR INDUCING MUCOSAL IMMUNITY |
US7227011B2 (en) | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
EP1100807A1 (en) | 1998-07-27 | 2001-05-23 | University Of Iowa Research Foundation | STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
US20010034330A1 (en) | 1998-08-10 | 2001-10-25 | Charlotte Kensil | Innate immunity-stimulating compositions of CpG and saponin and methods thereof |
AU5911899A (en) * | 1998-09-09 | 2000-03-27 | Genzyme Corporation | Methylation of plasmid vectors |
US20020065236A1 (en) * | 1998-09-09 | 2002-05-30 | Yew Nelson S. | CpG reduced plasmids and viral vectors |
US20020142974A1 (en) | 1998-09-11 | 2002-10-03 | Leonard D. Kohn | Immune activation by double-stranded polynucleotides |
WO2000020039A1 (en) | 1998-10-05 | 2000-04-13 | The Regents Of The University Of California | Methods and adjuvants for stimulating mucosal immunity |
AU6425999A (en) | 1998-10-09 | 2000-05-01 | Dynavax Technologies Corporation | Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens |
JP2002534968A (en) * | 1999-01-22 | 2002-10-22 | ザ スキーペンズ アイ リサーチ インスティテュート インコーポレイテッド | Activation of regulatory T cells by α-melanocyte stimulating hormone |
US6977245B2 (en) * | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
EP1176966B1 (en) | 1999-04-12 | 2013-04-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Oligodeoxynucleotide and its use to induce an immune response |
AU4642600A (en) | 1999-04-15 | 2000-11-02 | Regents Of The University Of California, The | Methods and compositions for use in potentiating antigen presentation by antigenpresenting cells |
AU4978100A (en) | 1999-04-29 | 2000-11-17 | Coley Pharmaceutical Gmbh | Screening for immunostimulatory dna functional modifyers |
ATE306938T1 (en) | 1999-06-29 | 2005-11-15 | Glaxosmithkline Biolog Sa | USE OF CPG AS AN ADJUVANT FOR HIV VACCINE |
US6514948B1 (en) * | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
EP1204425B1 (en) | 1999-08-19 | 2009-01-07 | Dynavax Technologies Corporation | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
AP2006003503A0 (en) * | 1999-09-25 | 2006-02-28 | Univ Iowa Res Found | Immunostimulatory nucleic acids. |
EP1220684B2 (en) | 1999-09-27 | 2010-07-14 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
US6949520B1 (en) * | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
US20020091095A1 (en) * | 1999-12-13 | 2002-07-11 | Phillips Nigel C. | Modulation of Fas and FasL expression |
US20020006403A1 (en) * | 1999-12-14 | 2002-01-17 | Xue-Zhong Yu | CD28-specific antibody compositions for use in methods of immunosuppression |
EP1322655B1 (en) * | 2000-01-14 | 2007-11-14 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Oligodeoxynucleotide and its use to induce an immune response |
AU3108001A (en) | 2000-01-20 | 2001-12-24 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing a th2 immune response |
AT409085B (en) | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | PHARMACEUTICAL COMPOSITION FOR IMMUNULATING AND PRODUCING VACCINES |
US6552006B2 (en) * | 2000-01-31 | 2003-04-22 | The Regents Of The University Of California | Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
US6613751B2 (en) * | 2000-02-23 | 2003-09-02 | The Regents Of The University Of California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
US6423539B2 (en) * | 2000-02-24 | 2002-07-23 | The Board Of Trustees Of The Leland Stanford Junior University | Adjuvant treatment by in vivo activation of dendritic cells |
US20020156033A1 (en) | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
US7157437B2 (en) | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US7129222B2 (en) * | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US20010046967A1 (en) * | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
US20020028784A1 (en) * | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
US20020098199A1 (en) | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
US20020107212A1 (en) | 2000-03-10 | 2002-08-08 | Nest Gary Van | Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences |
AU2001249609A1 (en) * | 2000-03-28 | 2001-10-08 | Department Of Veterans Affairs | Methods for increasing a cytotoxic T lymphocyte response in vivo |
AU2001251407A1 (en) | 2000-04-07 | 2001-10-23 | The Regents Of The University Of California | Synergistic improvements to polynucleotide vaccines |
AU2001275294A1 (en) * | 2000-06-07 | 2001-12-17 | Biosynexus Incorporated. | Immunostimulatory RNA/DNA hybrid molecules |
US20020165178A1 (en) | 2000-06-28 | 2002-11-07 | Christian Schetter | Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia |
BRPI0112928B1 (en) | 2000-07-27 | 2017-08-29 | Children's Hospital & Research Center At Oakland | A composition comprising preparations comprising outer membrane vesicles (OMV), microvesicles (MV) or both MVO and MV |
US20020198165A1 (en) | 2000-08-01 | 2002-12-26 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of gastric ulcers |
US7811592B2 (en) | 2000-08-16 | 2010-10-12 | Auburn University | Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of Chlamydia |
US20020091097A1 (en) * | 2000-09-07 | 2002-07-11 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of sexually transmitted diseases |
CA2423487C (en) | 2000-09-26 | 2015-12-15 | Hybridon, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
RU2257198C2 (en) | 2000-09-28 | 2005-07-27 | Чирон Корпорейшн | Microparticle composition and methods for their preparing |
WO2002034887A2 (en) | 2000-10-24 | 2002-05-02 | Schering Corporation | Maturation of dendritic cells |
KR100331952B1 (en) | 2000-11-23 | 2002-04-09 | 최수일 | The Composition Of Multipurpose High-Functional Alkali Solution, Preparation Thereof, And For The Use Of Nonspecific Immunostimulator |
US7666674B2 (en) * | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
US7354909B2 (en) * | 2001-08-14 | 2008-04-08 | The United States Of America As Represented By Secretary Of The Department Of Health And Human Services | Method for rapid generation of mature dendritic cells |
AU2002366710A1 (en) * | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
US8043622B2 (en) * | 2002-10-08 | 2011-10-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides |
JP4976653B2 (en) * | 2002-11-01 | 2012-07-18 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシス | Method for preventing infections caused by bioterrorism pathogens using immunostimulatory CpG oligonucleotides |
JP2008523084A (en) * | 2004-12-08 | 2008-07-03 | スリーエム イノベイティブ プロパティズ カンパニー | Immunostimulating combination and method |
WO2006065751A2 (en) * | 2004-12-13 | 2006-06-22 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods |
CA2620582C (en) * | 2005-08-31 | 2015-11-10 | Dennis M. Klinman | Methods of altering an immune response induced by cpg oligodeoxynucleotides |
US8053422B2 (en) * | 2008-12-04 | 2011-11-08 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-cancer oligodeoxynucleotides |
-
2001
- 2001-01-12 EP EP01902045A patent/EP1322655B1/en not_active Expired - Lifetime
- 2001-01-12 AU AU2001227889A patent/AU2001227889A1/en not_active Abandoned
- 2001-01-12 AT AT01902045T patent/ATE378348T1/en active
- 2001-01-12 DE DE60131430T patent/DE60131430T2/en not_active Expired - Lifetime
- 2001-01-12 WO PCT/US2001/001122 patent/WO2001051500A1/en active IP Right Grant
-
2002
- 2002-07-12 US US10/194,035 patent/US7521063B2/en not_active Expired - Lifetime
-
2007
- 2007-05-10 US US11/801,984 patent/US7919477B2/en not_active Expired - Lifetime
-
2011
- 2011-02-11 US US13/026,032 patent/US8232259B2/en not_active Expired - Fee Related
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998018810A1 (en) * | 1996-10-30 | 1998-05-07 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
WO1998040100A1 (en) * | 1997-03-10 | 1998-09-17 | Ottawa Civic Loeb Research Institute | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT |
WO1998049288A1 (en) * | 1997-04-30 | 1998-11-05 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and in vivo protection from infection |
WO1998052581A1 (en) * | 1997-05-20 | 1998-11-26 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
WO1998055495A2 (en) * | 1997-06-06 | 1998-12-10 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
WO1999051259A2 (en) * | 1998-04-03 | 1999-10-14 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
WO1999056755A1 (en) * | 1998-05-06 | 1999-11-11 | University Of Iowa Research Foundation | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
WO1999058118A2 (en) * | 1998-05-14 | 1999-11-18 | Cpg Immunopharmaceuticals Gmbh | METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8741869B2 (en) | 1999-04-12 | 2014-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US8389495B2 (en) | 1999-04-12 | 2013-03-05 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Olioodeoxynucleotide and its use to induce an immune response |
US8030285B2 (en) | 1999-04-12 | 2011-10-04 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US7521063B2 (en) * | 2000-01-14 | 2009-04-21 | The United States Of America As Represented By The Department Of Health And Human Services | Multiple CPG oligodeoxynucleotides and their use to induce an immune response |
US8232259B2 (en) | 2000-01-14 | 2012-07-31 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Multiple CpG oligodeoxynucleotide and their use to induce an immune response |
US7919477B2 (en) | 2000-01-14 | 2011-04-05 | The United States Of America As Represented By The Department Of Health And Human Services | Multiple CpG oligodeoxynucleotides and their use to induce an immune response |
US8124590B2 (en) | 2000-03-10 | 2012-02-28 | Dynavax Technologies Corporation | Biodegradable immunomodulatory formulations and methods for use thereof |
US7129222B2 (en) | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US7183111B2 (en) | 2000-03-10 | 2007-02-27 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US7250403B2 (en) | 2000-03-10 | 2007-07-31 | Dynavax Technologies Corporation | Biodegradable immunomodulatory formulations and methods for use thereof |
US8372413B2 (en) | 2000-12-27 | 2013-02-12 | Dynavax Technologies Corporation | Immunomodulatory polynucleotides and methods of using the same |
US9028845B2 (en) | 2001-06-21 | 2015-05-12 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same-IV |
WO2003014316A2 (en) | 2001-08-07 | 2003-02-20 | Dynavax Technologies Corporation | Immunomodulatory compositions, formulations, and methods for use thereof |
US8586555B2 (en) | 2001-08-07 | 2013-11-19 | Dynavax Technologies Corporation | Immunomodulatory compositions, formulations, and methods for use thereof |
WO2003020884A3 (en) * | 2001-08-14 | 2004-09-16 | Us Health | Method for rapid generation of mature dendritic cells |
WO2003020884A2 (en) * | 2001-08-14 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for rapid generation of mature dendritic cells |
EP1572122A2 (en) * | 2002-11-01 | 2005-09-14 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides |
US7758876B2 (en) | 2002-11-01 | 2010-07-20 | The United States Of America As Represented By The Department Of Health And Human Services | Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides |
US8481055B2 (en) | 2002-11-01 | 2013-07-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides |
EP1572122A4 (en) * | 2002-11-01 | 2008-04-09 | Us Gov Health & Human Serv | Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides |
US11312965B2 (en) | 2002-12-23 | 2022-04-26 | Trisalus Life Sciences, Inc. | Immunostimulatory sequence oligonucleotides and methods of using the same |
US7745606B2 (en) | 2002-12-23 | 2010-06-29 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
EP1992635A1 (en) | 2002-12-23 | 2008-11-19 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US8871732B2 (en) | 2002-12-23 | 2014-10-28 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US10196643B2 (en) | 2002-12-23 | 2019-02-05 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US9422564B2 (en) | 2002-12-23 | 2016-08-23 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
WO2004078772A1 (en) * | 2003-03-03 | 2004-09-16 | Doo-Sik Kim | Oligonucleotides for stimulating immune response |
US8008267B2 (en) | 2003-06-11 | 2011-08-30 | Idera Pharmaceuticals, Inc. | Stabilized immunomodulatory oligonucleotides |
US8946175B1 (en) | 2003-06-11 | 2015-02-03 | Idera Pharmaceuticals, Inc. | Stabilized immunomodulatory oligonucleotides |
WO2005001055A3 (en) * | 2003-06-11 | 2005-10-13 | Hybridon Inc | Stabilized immunomodulatory oligonucleotides |
US9809824B2 (en) | 2004-12-13 | 2017-11-07 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods |
WO2012160153A1 (en) | 2011-05-24 | 2012-11-29 | Assistance Publique - Hopitaux De Paris | Agents for treating tumours |
WO2016103703A1 (en) * | 2014-12-25 | 2016-06-30 | 国立研究開発法人医薬基盤・健康・栄養研究所 | Non-aggregating immunostimulatory oligonucleotides |
US11268098B2 (en) | 2014-12-25 | 2022-03-08 | National Institutes Of Biomedical Innovation, Health And Nutrition | Non-aggregating immunostimulatory oligonucleotides |
WO2016183370A1 (en) | 2015-05-13 | 2016-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Synthetic immunosuppressive oligodeoxynucleotides reduce ischemic tissue damage |
WO2016183371A1 (en) | 2015-05-13 | 2016-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for the treatment or prevention of ischemic tissue damage |
WO2017192874A1 (en) | 2016-05-04 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Albumin-binding immunomodulatory compositions and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
US7521063B2 (en) | 2009-04-21 |
EP1322655B1 (en) | 2007-11-14 |
US8232259B2 (en) | 2012-07-31 |
EP1322655A1 (en) | 2003-07-02 |
US20030144229A1 (en) | 2003-07-31 |
US7919477B2 (en) | 2011-04-05 |
US20110189267A1 (en) | 2011-08-04 |
DE60131430D1 (en) | 2007-12-27 |
DE60131430T2 (en) | 2008-10-16 |
AU2001227889A1 (en) | 2001-07-24 |
US20080069825A1 (en) | 2008-03-20 |
ATE378348T1 (en) | 2007-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8741869B2 (en) | Oligodeoxynucleotide and its use to induce an immune response | |
EP1322655B1 (en) | Oligodeoxynucleotide and its use to induce an immune response | |
JP6434204B2 (en) | Compositions and methods relating to the formulation of oligonucleotides | |
EP1390495B1 (en) | Immunostimulatory oligodeoxynucleic molecules | |
JP4383534B2 (en) | Combinatorial motif immunostimulatory oligonucleotides with improved activity | |
WO2015108046A1 (en) | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent | |
US8227446B2 (en) | Oligodeoxynucleotide and its use to induce an immune response | |
JP5101282B2 (en) | Therapeutic uses of CpG oligodeoxynucleotides for skin diseases | |
JP2006512927A (en) | 5 'CPG nucleic acids and methods of use thereof | |
KR20090057468A (en) | Compositions of tlr ligands and antivirals | |
CN101821392B (en) | RNA sequence motifs in the context of defined inter-nucleotide linkages inducing specific immune modulatory profiles | |
KR20100068422A (en) | Immune stimulatory oligonucleotide analogs containing modified sugar moieties | |
WO2006053861A1 (en) | Oligonucleotides that induce the secretion of gm-csf | |
JP2009028031A (en) | Phosphate-modified oligonucleotide analog with enhanced immunostimulatory activity | |
EP1950296B1 (en) | Oligodeoxynucleotide and its use to induce an immune response | |
MXPA06004891A (en) | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10194035 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001902045 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 2001902045 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001902045 Country of ref document: EP |